Robert J. Alpern - 30 Jun 2022 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role: Director
Signature: Steven L. Scrogham, attorney-in-fact for Robert J. Alpern
Issuer symbol: ABBV
Transactions as of: 30 Jun 2022
Transactions value $: $7,199
Form type: 4
Filing time: 05 Jul 2022, 17:25:55
Previous filing: 16 Jun 2022
Next filing: 04 Oct 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABBV	Stock Equivalent Units	Award	$7.2K	+47	+0.56%	$153.16	8.46K	30 Jun 2022	Common Stock	47	$153.16	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
F2	Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Content

Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.